Elektrofi and IPA collaborate on Covid-19 antibody development
Elektrofi and IPA collaborate on Covid-19 antibody development

Elektrofi and IPA collaborate on Covid-19 antibody development

Elektrofi has entered into one partnership with ImmunoPrecise Antibodies (IPA) to develop a high concentration formulation of the latter’s Covid-19 antibody cocktail, PolyTope TATX-03.

The Alliance intends to produce a data package required to submit a new drug application (IND) to the Food and Drug Administration (FDA) for TATX-03E, an alternative formulation of TATX-03 that can be administered by itself in the non-health environment.

TATX-03E could potentially tackle the requirements for ready-to-implement, low-volume, stable, self-injectable formulation.

By combining the efforts, the companies plan to formulate the TATX-03E for a stable and fast consumer supply.

This drug product will be developed to be suitable for meeting unmet needs in the field, rapid spread and increased dosing frequency for immunocompromised people who need continued access to treatments and prophylaxis.

In the initial phase, IPA and Elektrofi will begin feasibility studies of formulations and subsequent IND-activating, non-clinical studies to validate the safety and efficacy of TATX-03’s new formulation.

Elektrofi’s agreement with the US Department of Defense (DoD) Defense Health Agency (DHA) Small Business Innovation Research (SBIR) Program will support the collaboration between the companies.

Electrofi Scientific Strategy Director Daniel Dadon said: “We are impressed with the neutralizing activity that ImmunoPrecise’s antibody cocktail is demonstrating against current variants of concern, including Omicron.

“Almost all other programs we’ve researched working with do not show the ability to neutralize so many variants.

“We look forward to working with IPA to develop a product that can potentially improve access to this class of life-saving drugs and reduce the burden on healthcare systems.”

In February 2020, IPA started a research program for the development of vaccines and therapeutic antibodies for Covid-19.

Related companies

Leave a Reply

Your email address will not be published.